Other authors have also shown amelioration of the AD phenotype with nilotinib, which is perceived to be the most CNS penetrating c-Abl inhibitor among the FDA-approved drugs (Turner et al., 2020; La Barbera et al., 2021). Here, ABL1 is linked to Alzheimer disease.